

Page 1 of 1 Form PTO-1449 Atty. Docket No. Serial No. **U.S. Department of Commerce** 10/272,958 67705/JPW/GJG/NDP Patent and Trademark Office Applicants: Eran Blaugrund et al. INFORMATION DISCLOSURE CITATION Filing Date (Use several sheets if necessary) November 13, 2003 **U.S. PATENT DOCUMENTS** Class Subclass Filing Date Examiner Document Number Date Name Initial if Appropriate FOREIGN PATENT DOCUMENTS Translation Document Number Date Country Class Subclass Yes OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Turner MR, et al., (2001) The King's data base 1990-2000: An analysis of the effect on survival of interventions in ALS. ALS and Other Motor Neuron Disorders, 2(Suppl. 2):43; and Traynor BJ, et al., (2001) Riluzole and prognosis in amyotrophic lateral sclerosis: Findings of the Irish

amyotrophic lateral sclerosis register over a five year study period 1995-2000. ALS and Other Motor Neuron Disorders, 2(Suppl. 2):43-4;

Wong PC, et al., (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron diseases characterized by vacuolar degeneration of mitochondria. Neuron, 14:1105-16.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initiabif citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: Eran Blaugrund et al.

Serial No.: 10/712,958 Filed: November 13, 2003

Exhibit A

SEP 1 3 ZOU SEP

EXAMINER

Page 1 of 3 Atty. Docket No. Serial No. Form PTO-1449 U.S. Department of Commerce 67705/JPW/GJG/MML 10/772.938 Patent and Trademark Office Applicants: Eran Blaugrund et al. INFORMATION DISCLOSURE CITATION Filing Date (Use several sheets if necessary) November 13, 2003 U.S. PATENT DOCUMENTS Subclass Class Filing Date Examiner Document Number Date Name Initial if Appropriate 2/7/95 Youdim, et al. 6 9/26/95 Youdim, et al.; 10/10/95 Youdim,et al.; 9/16/97 Youdim, et al.; 11/19/96 Youdim, et al.; Youdim, et al.; 7/2/96 2/4/97 Youdim, et al.; 7/28/98 Youdim, et al.; Youdim, et al.; 5/21/96 4/6/99 Youdim, et al.; 4/28/98 Youdim, et al.; 2*171*95 Youdim, et al.: 00 10 0 1/15/04 Blaugrund et al.: FOREIGN PATENT DOCUMENTS Translation Document Number Class Subclass -Date Country Yes No WO 20 03 07 2 9/4/2003 PCT; PCT: WO 20 04 04 5 6/3/04 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Bensimon G, et al., (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med., 330(9):585-91; Bentué-Ferrer D, et al., (1996) Monoamine Oxidase B Inhibitors. CNS Drugs., 6(3):217-36; Doble A. (1996) The pharmacology and mechanism of action riluzole. Neurology, 47 (Suppl. 1):S233-41; Eliash S, et al. (2001) "Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats. J. Neural Transm., 108:909-23; Ferrante RJ, et al., (1997) Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann. Neurol., 42:326-34; 'Guidance for Industry: In vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling," U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), November 1999; Gurney ME, et al., (1994) Motor neuron degeneration in mice that express a human superoxide dismutase mutation. Science, 264:1772-5;

DATE CONSIDERED

conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in

Applicants: Eran Blaugrund et al.

14/1/2 958

Serial No.: 10/712,958 Filed: November 13, 2003

Exhibit A

Page 2 of 3

Form PTO-	1449							t of Comme demark Offi		Atty. Dock	ket No. W/GJG/MML	Serial N 1 <del>0/772,</del>		10/112958								
										Applicant	s: Eran Blaugr	11										
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										Filing Date												
								IIS DAT	ENT DOCUMENTS	p 10 10 11 11 11 11 11 11 11 11 11 11 11			. <del>I</del>									
Examiner	D	ocun	nent	Nur	nbe	r		Date	Name	Class	Subclass	Filing I										
Initial			7									if Appr	opriate									
-		+-	$\vdash$	$\vdash$		⊢┼	$\dashv$					<del> </del>		•								
<del>                                     </del>	$\dashv$	╅	1		_	<del>                                     </del>	_			<del></del>												
		1-				$\Box$		•				1										
														ĺ								
							]	FOREIGN I	PATENT DOCUMENT	rs												
	Ъ	ocun	nent	Nur	nhe	r	П	Date	Country	Class	Subclass	Transl	ation									
	٦								000000	-		Yes	No									
		$\top$				П	7	·····														
		$\top$					٦						Ţ-	}								
						П	1		,													
ļ			OPE FE	2D I		~ X 73.4	ER	TC (Indus)	ng Author, Title, Date	Dortinant I	Pages Fta )		<del></del>									
1	G								itamin E, riluzole, and			model of	familia									
1										Bro-Louis				·								
1	amyotrophic lateral sclerosis. Ann. Neurol., 39:147-57; Huang W, et al., (1999) Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor,													]								
	against closed head injury in the mouse. Eur. J. Pharmacol., 336:127-35;																					
	K	Kong J, et al., (1998) Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic																				
	la I	lateral sclerosis in mice expressing a mutant SOD1. J. Neurosci., 18:3241-50;																				
	Lacomblez L, et al., (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet, 347:1425-31;  Lange DJ, et al., (1998) Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for											1										
	tr	eatme	ent of	f am	yotı	rophic	: la	iteral scleros	is. Arch Neurol., 55(1):	93-6;			f amyotrophic set, 347:1425- lled trial for unsm.,									
						(199	9)	Antiglutama	te therapy in ALS - whi	ch is the nex	t step? J. Neural	Transm.	,									
														1								
	M	laruy	ama	W, 6	et al	., (20	00	Neurotoxin	sclerosis. Arch Neurol., 55(1):93-6; lutamate therapy in ALS – which is the next step? <u>J. Neural Transm.</u> , rotoxins induce apoptosis in dopamine neurons: protection by N- ninoindan, rasagiline and TV1022. <u>J. Neural Transm.</u> , 60(Suppl):171-86;													
	55(Suppl.):79-96;  Maruyama W, et al., (2000) Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. J. Neural Transm., 60(Suppl):171-86;  Maruyama W, et al. (2001) Transfection-enforced bcl-2 overexpression and an anti-Parkinson drug,											-										
	propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. J. Neural Transm., 60(Suppl):171-86;																					
	er	ndoge	nous	do	pam	inerg	ic i	neurotoxin, l	N-methyl(R)salsolinol.	. Neurochem	<u>1.</u> , 78:727-35;											
	P	hysic	ians	Desi	k Re	eferer	cė	(2002), p. 7	72-5					]								
		Speiser Z, et al., (1999) Studies with rasagiline, a monamine oxidase-B inhibitor, in experimental focal																				
									06:593-606;			6.1	<del> </del>	4								
	/ T	rayno	or BJ	, et a	al., (	(2001	) F	liluzole and	prognosis in amyotroph er a five year study per	ic lateral scie	crosis: Findings	of the Iris	il Nauron									
						. Sciei . 2):4:			er a rive year study per	1993-200	No. ALS and On	iel Midior	IVEUION									
T									ata base 1990-2000: An	analysis of t	he effect on sur	vival of		1								
									lotor Neuron Disorders					_]								
EXAMINER				=	>.			DATE CON	SIDERED													
		>	_					-11.12.001	12/21/66													
*EXAMINED	: Initia	Lifcir	ation	conei	dere	d who	the	r or not citation	is in conformance with MI	EP 609: Draw	line through citation	n if not in		1								
									kt communication to applica					. ·								

Page 3 of 3

Serial No.

L 10/772,958 /0/1/2958

Form PTO	-144	9							nt of Comme demark Off	Atty. Dock 67705/JP	tet No. W/GJG/MML	Serial No. 10/772,958				
INFORMATION DISCLOSURE CITATION												Applicants: Eran Blaugrund et al.				
(Use several sheets if necessary)												r 13, 2003	Group /6/1)			
									U.S. PAT	TENT DOCUMENTS				,		
Examiner Initial		Doc	eum	ent	Nu	mbe	r	r	Date	Name	Class	Subclass	Filing Date if Appropriate			
									·		<u> </u>					
	FOREIGN PATENT DOCUMENTS  Class Substance Translation															
		Doc	um	ent	Nu	mbe	r 		Date	Country	Class	Subclass	Yes	No		
				_	_		_		·			1.				
		÷	-	-	$\vdash$	$\vdash$	_						<del>                                     </del>	ļ		
													ļ			
		-	-	-	$\vdash$	-		-								
				Ŀ												
2	_	amy	lhat otro	er ophi	S, e	t al	., (2 scl	200e eros	0) Mitochon is. <u>Brain,</u> 12		in skeleta	l muscle patier				
		Wong PC, et al., (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron diseases characterized by vacuolar degeneration of mitochondria. Neuron, 14:1105-16; and														
0/	•									(N-propargyl-1R(+)-ami r. J. Pharmacol., 132:500		selective and po	tent inhi	bitor of		
/																
		_														
											· · · · · · · · · · · · · · · · · · ·					
EXAMINE	R.		= >		2	<u>&gt;</u> :			DATE CON	ISIDERED 12	21/06					
										n is in conformance with MPE xt communication to applicant	P 609: Draw	ine through citation	n if not in			